Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Call for input regarding microcurrent treatment for anxiety, depression, and sleep problems for the “New Methods” framework in Norway

Norway has a national system for the introduction of new health technologies within the specialist health service (“New Methods” framework) through either a national or hospital-based health technology assessment. This framework is mandatory for all innovations before being funded.

In May 2023, Ordering Forum for the “New Methods” framework invited interested parties regarding microcurrent treatment for anxiety, depression, and sleep problems (e.g., Alpha-Stim cranial electrotherapy stimulation). Information shall be submitted no later than August 8, 2023. Ordering Forum will be held on August 28, 2023, to decide whether the method will undergo evaluation at the national level.

See more information in Norwegian here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Contact us to get a free, three-month, no-obligation trial.